In severe hemophilia A, early prophylaxis and regular physical activity were linked to lower joint damage in a real-world ...

Columnist Jennifer Lynne wraps up a series with hemophilia advocate Lee Hall, who emphasizes the importance of learning our history.

Medically reviewed by Doru Paul, MD Key Takeaways Hemophilia A is a bleeding disorder caused by a deficiency in factor VIII. Treatment options for hemophilia A include replacing factor VIII and gene ...

Henry Ford Health has treated the first Michigan patient outside clinical trials with Roctavian, the newly approved gene ...

Karnataka government launched 'Kusuma Sanjeevini' programme under which patients suffering from haemophilia will be provided ...

Early prophylaxis reduces bone loss in haemophilia, while delayed or absent treatment increases osteoporosis risk.

Less than a year after approval, Pfizer said it plans to discontinue its hemophilia B gene therapy fidanacogene elaparvovec (Beqvez) across all global markets, citing weak demand. "Pfizer has made the ...

Gene therapy is part of an increasingly large collection of research fields: those with a huge, useless backlog of innovations. Gene therapy researchers have spent decades developing amazing, ...

The Karnataka government has launched the 'Kusuma Sanjeevini' scheme, targeting haemophilia patients. It aims to prevent bleeding episodes rather than treat them, utilizing modern preventive therapy.

Living with hemophilia B can be scary. But treatment is so effective that people who have hemophilia generally live just as long as people who don’t have the ...

Karnataka launches 'Kusuma Sanjeevini' program, providing free prophylactic treatment and transport for hemophilia patients, enhancing their quality of life.

Karnataka is now providing free preventive treatment for haemophilia patients. A new drug, Emicizumab, will be available at 36 centres. This initiative aims to stop bleeds and joint pain, allowing ...